A detailed history of Vanguard Group Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Vanguard Group Inc holds 3,243,473 shares of PTGX stock, worth $154 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,243,473
Previous 3,192,971 1.58%
Holding current value
$154 Million
Previous $92.4 Million 21.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$24.66 - $34.8 $1.25 Million - $1.76 Million
50,502 Added 1.58%
3,243,473 $112 Million
Q1 2024

May 10, 2024

BUY
$21.79 - $32.15 $851,008 - $1.26 Million
39,055 Added 1.24%
3,192,971 $92.4 Million
Q4 2023

Feb 14, 2024

SELL
$14.05 - $23.44 $1.05 Million - $1.75 Million
-74,478 Reduced 2.31%
3,153,916 $72.3 Million
Q3 2023

Nov 14, 2023

BUY
$16.68 - $23.66 $1.35 Million - $1.91 Million
80,639 Added 2.56%
3,228,394 $53.8 Million
Q2 2023

Aug 14, 2023

SELL
$18.02 - $29.36 $1.69 Million - $2.75 Million
-93,538 Reduced 2.89%
3,147,755 $86.9 Million
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $1.55 Million - $3.64 Million
143,579 Added 4.63%
3,241,293 $74.5 Million
Q4 2022

Feb 10, 2023

BUY
$7.36 - $11.17 $1.14 Million - $1.73 Million
154,947 Added 5.27%
3,097,714 $33.8 Million
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $1.63 Million - $2.44 Million
208,002 Added 7.61%
2,942,767 $24.8 Million
Q2 2022

Aug 12, 2022

BUY
$7.06 - $25.52 $2.86 Million - $10.3 Million
404,691 Added 17.37%
2,734,765 $21.6 Million
Q1 2022

May 13, 2022

SELL
$23.34 - $36.08 $422,267 - $652,759
-18,092 Reduced 0.77%
2,330,074 $55.2 Million
Q4 2021

Feb 14, 2022

SELL
$17.63 - $37.1 $99,080 - $208,502
-5,620 Reduced 0.24%
2,348,166 $80.3 Million
Q3 2021

Nov 12, 2021

BUY
$12.95 - $49.69 $851,488 - $3.27 Million
65,752 Added 2.87%
2,353,786 $41.7 Million
Q2 2021

Aug 13, 2021

BUY
$25.57 - $44.88 $58.5 Million - $103 Million
2,288,034 New
2,288,034 $103 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.34B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.